In brief: BresaGen, Premier Bionics, Panbio, Eqitx
Friday, 03 February, 2006
BresaGen has concluded an agreement with Indian firm BV BioCorp, to register and distribute BresaGen's G-CSF for leukaemia and an undisclosed product in India, Sri Lanka, Bangladesh, and Nepal. Details of the agreement are confidential, but BresaGen anticipates the projects will be developed and clinical trials for registration will commence in early 2007.
Medic Vision, a wholly owned subsidiary of Premier Bionics (ASX:PBI) has signed a contract with German company VR Magic for the sale and distribution of the Eyesis Ophthalmossurgical Simulator, which provides training for vitreo-retinal and cataract surgery, in Australia and New Zealand with rights to sell into the Asia Pacific region.
Panbio (ASX:PBO) has appointed Peter Arnison, a former governor of Queensland, as the company's new chairman.
Dr Nick Ede has resigned from his position as chief operating officer and general manager of Eqitx (ASX:EQX) subsidiary ZingoTX to pursue other career options.
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
